SCHEMBL62881

SCHEMBL62881

C[C@](N)(CS)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL62882 1.00
SCHEMBL64140 1.00
Hydrochloric Acid SCHEMBL1132702 0.97
Hydrochloric Acid SCHEMBL27622305 0.97 GGT1 (0.46)
Hydrochloric Acid SCHEMBL1132934 0.97
Hydrochloric Acid SCHEMBL14832376 0.97 GGT1 (0.46)
Hydrochloric Acid SCHEMBL1132932 0.97
Hydrochloric Acid SCHEMBL14832377 0.97 GGT1 (0.46)
SCHEMBL11048293 0.97
SCHEMBL11048301 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2564 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116921-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS INC (US) 2026-04-30 US claimed
EP-4658374-A1 METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Janssen Pharmaceutica NV (BE) 2025-12-10 EP claimed
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
CN-119192296-A Polypeptide compound, pharmaceutical composition and application 杭州禾泰健宇生物科技有限公司 2024-12-27 CN claimed
US-20240409598-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN BIOTECH INC (US) 2024-12-12 US claimed
WO-2024163643-A1 METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2024-08-08 WO claimed
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-07-11 US claimed
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-07-04 US claimed
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
CN-118063554-A Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases 詹森生物科技公司 2024-05-24 CN claimed
EP-1550725-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE KANEKA CORPORATION (JP) 2005-07-06 EP claimed
EP-1541692-A1 PROCESS FOR PRODUCING L-a-METHYLCYSTEINE DERIVATIVE KANEKA CORPORATION (JP) 2005-06-15 EP claimed
EP-1529037-A2 SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF Genzyme Corporation (US) 2005-05-11 EP claimed
US-20040122099-A1 Process for preparing S-(2-aminoethyl)-2-methyl-L-cysteine WUTS PETER GUILLAUME MARIE (US) 2004-06-24 US claimed
WO-2004039772-A1 PROCESS FOR PREPARING S-(2-AMINOETHYL)-2-METHYL-L-CYSTEINE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-05-13 WO claimed
US-20040024224-A1 Synthesis of 2-alkyl amino acids GENZYME CORPORATION (US) 2004-02-05 US claimed
US-20040006224-A1 Synthesis of 2-alkyl amino acids GENZYME CORPORATION 2004-01-08 US claimed
US-20030236404-A1 Synthesis of 2-alkylcysteine via phase transfer catalysis GENZYME CORPORATION 2003-12-25 US claimed
WO-2003097622-A2 SYNTHESIS OF 2-ALKYLCYSTEINES, 2-(HYDROXYLATED PHENYL)-4-ALKYLTHIAZOLINE-4-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF GENZYME CORPORATION (US) 2003-11-27 WO claimed
US-4487780-A SUBSTITUTED CYSTEINE COMPOUNDS SCHEINBERG ISRAEL H 1984-12-11 US claimed